Abeona Therapeutics Inc. (ABEO) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1330 Avenue of the Americas
Cleveland, NY 10019
United States of America (the)
Phone
646 813 4701
Sector
Healthcare
Industry
Biotechnology
Employees
136
First IPO Date
September 19, 1980
| Name | Title | Pay | Year Born |
| Vishwas Seshadri | President, Chief Executive Officer & Director | 1.52M | 1976 |
| Brendan O'Malley | Chief Legal Officer | 783,926 | 1969 |
| Joseph Walter Vazzano | Chief Financial Officer | 898,465 | 1984 |
| Jon Voss | Vice President & Head of Quality | 0 | 1960 |
| Madhav Vasanthavada | Senior Vice President, Chief Commercial Officer & Head of Business Development | 0 | 1979 |
| James A. Gow | SVP, Head of Clinical Development & Medical Affairs | 0 | 1967 |
| Brian Kevany | Chief Technical & Scientific Officer | 0 | N/A |
| Megan Callan | Vice President & Head of Quality | 0 | N/A |
| Gregory Gin | Vice President of Investor Relations & Corporation Communications | 0 | N/A |
| Carl Denny | Senior Vice President of Regulatory Affairs | 0 | N/A |
| Gianine Esposito | Senior VP & Chief People Officer | 0 | N/A |
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.